Alumis Inc. has disclosed a stock transaction involving its Chief Medical Officer, Drappa Jorn, who sold 593 shares of common stock. This sale occurred on November 2, 2026, and was executed as part of the company’s policy requiring sell-to-cover to meet tax obligations arising from the vesting of restricted stock units.

This transaction is significant as it highlights how executives in the pharmaceutical preparations sector manage their stock compensation. The sale price for the shares ranged from $6.41 to $6.52, with a weighted average sale price of $6.52.

Background

Alumis Inc., traded on the Nasdaq under the ticker ALMS, operates within the pharmaceutical preparations industry, classified under SIC 2834. The company has undergone several name changes, previously known as Esker Therapeutics, Inc. and FL2021-001, Inc. Its recent filings include multiple Form 4 submissions, indicating active management of stock ownership.

What the Filing Says

The SEC filing, accession number 0001789317-26-000009, states, "The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person." This indicates that the transaction was not a choice made by Jorn but rather a necessity to cover tax liabilities.

Impact

This transaction may affect shareholders and potential investors in Alumis Inc. by providing insight into the company's executive compensation practices. It also reflects broader trends within the pharmaceutical industry as companies navigate stock compensation strategies and their implications for executive financial management.

What's Next

The filing does not say what happens next.